Catalyst Dossier · compiled by CeliA 🧫

Basel Medical Group Ltd (BMGL)

Services-Offices & Clinics of Doctors of Medicine · market cap $12M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2027-03-15 (est.)

Phase 3

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2027-03-15 (est.)Phase 3 · Colchicineimp 9/10

Pipeline

Asset	Phase	Indication
LSD	Phase 2	Major Depressive Disorder
Paclitaxel dosing according to SmPC	Phase 3	Carcinoma, Non-Small-Cell Lung
Interferon beta-1b group	Phase 2	Relapsing-remitting Multiple Sclerosis
Interferon beta 1b	Phase 2	Multiple Sclerosis
Vortioxetine	Phase 2	Glioblastoma
CHILD-IVITAB	Phase 2	Scabies
Dapansutrile	Phase 2	Diabetes Mellitus, Type 2
Cinacalcet	Phase 2	Memory Functions
Salbutamol	Phase 2	Memory Functions
Colchicine	Phase 3	Atrial Fibrillation
Fampridine SR	Phase 2	Working Memory
High-dose influenza vaccine	Phase 3	Influenza
Vitamin D3	Phase 3	Improve Healthy Ageing in Seniors; Prevent Disease at Older Age

Price & technical context

3-month

-64.6%

6-month

-85.1%

12-month

—

52-wk range

$0.70–$6.08

vs 50-day MA

-48.6%

vs 200-day MA

-73.4%

Realized vol

271.7%

Max drawdown

-88.5%

Daily closes through 2025-12-11. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for BMGL (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 13 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.